| Renal Cell Carcinoma
Fotivda vs Lenvima
Side-by-side clinical, coverage, and cost comparison for renal cell carcinoma.Deep comparison between: Fotivda vs Lenvima with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLenvima has a higher rate of injection site reactions vs Fotivda based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lenvima but not Fotivda, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Fotivda
Lenvima
At A Glance
Oral
Once daily
VEGFR tyrosine kinase inhibitor
Oral
Once daily
Multi-kinase inhibitor
Indications
- Renal Cell Carcinoma
- Differentiated Thyroid Gland Carcinoma
- Renal Cell Carcinoma
- Liver carcinoma
- Endometrial Carcinoma
Dosing
Renal Cell Carcinoma 1.34 mg orally once daily for 21 days on treatment followed by 7 days off treatment (28-day cycle); reduce to 0.89 mg once daily for moderate hepatic impairment.
Differentiated Thyroid Gland Carcinoma 24 mg orally once daily until disease progression or unacceptable toxicity.
Renal Cell Carcinoma (first-line, with pembrolizumab) 20 mg orally once daily in combination with pembrolizumab 200 mg IV infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity or up to 2 years.
Renal Cell Carcinoma (previously treated, with everolimus) 18 mg orally once daily in combination with everolimus 5 mg orally once daily until disease progression or unacceptable toxicity.
Liver carcinoma 12 mg orally once daily for patients >=60 kg or 8 mg orally once daily for patients <60 kg, until disease progression or unacceptable toxicity.
Endometrial Carcinoma 20 mg orally once daily in combination with pembrolizumab 200 mg IV infusion over 30 minutes every 3 weeks until unacceptable toxicity or disease progression.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) fatigue, hypertension, diarrhea, decreased appetite, nausea, dysphonia, hypothyroidism, cough, stomatitis
Serious bleeding, venous thromboembolism, arterial thromboembolism, acute kidney injury, hepatobiliary disorders
Postmarketing gastrointestinal perforation, pancreatitis
Most common (>=20%) Hypertension, fatigue, diarrhea, arthralgia/myalgia, decreased appetite, decreased weight, nausea, stomatitis, headache, vomiting, proteinuria, palmar-plantar erythrodysesthesia syndrome, abdominal pain, dysphonia, hypothyroidism, hemorrhagic events, rash, musculoskeletal pain.
Serious Hepatic encephalopathy, hepatic failure, cardio-respiratory arrest, sepsis, myocardial infarction, pneumonitis, acute kidney injury, renal failure, dehydration, thrombocytopenia, dyspnea, anemia.
Postmarketing Pancreatitis, impaired wound healing, cholecystitis, nephrotic syndrome, arterial aneurysms/dissections/rupture.
Pharmacology
Tivozanib is a tyrosine kinase inhibitor that inhibits phosphorylation of VEGFR-1, VEGFR-2, and VEGFR-3, as well as c-kit and PDGFR-beta, thereby inhibiting angiogenesis, vascular permeability, and tumor growth including human renal cell carcinoma.
Lenvatinib is a multi-kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 kinase activities as well as FGFR1-4, PDGFRA, KIT, and RET, suppressing pathogenic angiogenesis and tumor growth; in combination with pembrolizumab or everolimus, it demonstrates enhanced antiangiogenic and antitumor activity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Fotivda
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
Lenvima
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Fotivda
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Lenvima
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Fotivda
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Lenvima
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Renal Cell Carcinoma (RCC): Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Lenvima.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FotivdaView full Fotivda profile
LenvimaView full Lenvima profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.